All In Biotech

Drug Trial Radar · NCT07276997

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

A Phase 2, Multicenter, 6-Week, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Icalcaprant in Subjects With Major Depressive Disorder

Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 195 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

195

Planned (sponsor's estimate)

Start

Dec 18, 2025

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Dec 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, tiredness, changes in eating habits, and aches and pains. This study will assess the changes in disease activity and adverse events of oral Icalcaprant in adult participants with major depressive disorder who are currently experiencing a major depressive episode (MDE). Icalcaprant is an investigational drug being developed for the treatment of depressive episodes in adult participants with major depressive disorder. Participants are placed in 1 of 3 groups, called treatment arms. There is a 1 in 3 chance that a participant will be assigned to placebo treatment. Around 195 adult participant with major depressive disorder will be enrolled in approximately 35 sites in North America. Participants will receive oral capsules of Icalcaprant or matching placebo once daily for 6 weeks, with a 30-day safety follow-up. There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Major Depressive Disorder

Interventions

  • IcalcaprantDrug

    Oral Capsules

  • Placebo for IcalcaprantDrug

    Oral Capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score.Time frame: Up to approximately 6 weeks
  2. Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 10 weeks

Locations

33 sites in 1 country. Site status is shown where the registry gives one.

  • Harmonex /ID# 277517

    Dothan, Alabama · Recruiting

  • Ima Clinical Research Phoenix (Alea) /ID# 277516

    Phoenix, Arizona · Recruiting

  • Preferred Research Partners /ID# 279206

    Little Rock, Arkansas · Recruiting

  • Woodland International Research Group /ID# 277605

    Little Rock, Arkansas · Recruiting

  • Advanced Research Center /ID# 277537

    Anaheim, California · Recruiting

  • Sun Valley Research Center /ID# 277513

    Imperial, California · Recruiting

  • Synergy San Diego /ID# 277553

    Lemon Grove, California · Recruiting

  • Accellacare - Long Beach /ID# 279181

    Long Beach, California · Recruiting

  • CenExel CNR /ID# 277533

    Sherman Oaks, California · Recruiting

  • Inland Psychiatric Medical Group /ID# 279275

    Temecula, California · Recruiting

  • Sunwise Clinical Research /ID# 277555

    Walnut Creek, California · Recruiting

  • CenExel Hollywood FL /ID# 278200

    Hollywood, Florida · Recruiting

  • Cns Healthcare - Jacksonville /ID# 277658

    Jacksonville, Florida · Recruiting

  • GMI Florida - Central Miami Medical Institute /ID# 278218

    Miami, Florida · Recruiting

  • Clinical Neuroscience Solutions - Orlando - East South Street /ID# 277558

    Orlando, Florida · Recruiting

  • EquiPath Health & Research Tampa Bay, LLC /ID# 279128

    Riverview, Florida · Recruiting

  • Trialmed /ID# 277601

    Atlanta, Georgia · Recruiting

  • Evergreen Clinical Trials - Norcross /ID# 279421

    Norcross, Georgia · Recruiting

  • Flourish Research - Great Lakes Clinical Trials /ID# 278201

    Chicago, Illinois · Recruiting

  • Amr Conventions Research /ID# 277547

    Warrenville, Illinois · Recruiting

  • Redbird Research /ID# 277485

    Las Vegas, Nevada · Recruiting

  • Ima Clinical Research - Manhattan /ID# 278212

    New York, New York · Recruiting

  • Manhattan Behavioral Medicine /ID# 277910

    New York, New York · Recruiting

  • Quest Therapeutics of Avon /ID# 277550

    Avon Lake, Ohio · Recruiting

  • OSU Psychiatry Department /ID# 277529

    Columbus, Ohio · Recruiting

  • Sooner Clinical Research /ID# 277659

    Oklahoma City, Oklahoma · Recruiting

  • Clinical Neuroscience Solutions /ID# 278192

    Memphis, Tennessee · Recruiting

  • Austin Clinical Trial Partners /ID# 279321

    Austin, Texas · Recruiting

  • Community Clinical Research - Cross Park Drive /ID# 277935

    Austin, Texas · Recruiting

  • Houston Clinical Trials - Bellaire /ID# 277551

    Bellaire, Texas · Recruiting

  • Pillar Clinical Research - Richardson /ID# 276764

    Richardson, Texas · Recruiting

  • Northwest Clinical Research Center /ID# 277484

    Bellevue, Washington · Recruiting

  • Core Clinical Research /ID# 277518

    Everett, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.